Treatment with paclitaxel–resveratrol-matrix-coated peripheral balloon angioplasty is linked with significantly less in-lesion late lumen loss (LLL) and lower target lesion revascularization rates (TLR) than treatment with plain old balloon angioplasty (POBA), researchers reported in Cardiovascular and Interventional Radiology.
Vessel recoil and neointimal hyperplasia may limit the ability of percutaneous transluminal angioplasty to treat PAOD. To reduce the rate of restenosis, physicians often use drug-coated balloons (DCB) to deliver drugs to the arterial wall, with the hope of lessening the rate of restenosis.
The randomized controlled trial included 153 patients with symptomatic peripheral artery occlusive disease (PAOD) in femoro-popliteal lesions. Patients had a mean lesion length of 13.2 ± 10.4 cm with target lesion total occlusions in 26.1% of all patients.
The patients were randomized to receive DCB or POBA, and the study’s results showed that patients in the DCB group had significantly less in-lesion LLL at 6 months when compared with those in the POBA group.
When evaluated at 12 months, patients in the DCB group had a significantly lower TLR rate compared with patients in the POBA group. Additionally, there was an increase in censored walking distance for DCB patients that indicates an advantage to undergoing DCB angioplasty rather than standard POBA.
Safety outcomes showed no differences in mortality between the two groups. During the 6 to 8 month follow-up period, there was only one minor target limb amputation in the DCB group.
“Drug-coated balloon angioplasty based on a paclitaxel–resveratrol matrix significantly reduced in-lesion late lumen loss at 6–8 months as compared to uncoated balloon angioplasty in patients with femoro-popliteal lesions,” the researchers concluded.
Tepe G, Gögebakan Ö, Redlich U, et al. Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter. Cardiovasc Intervent Radiol. 2017 Jun 28. doi: 10.1007/s00270-017-1713-2. [Epub ahead of print].